Metrics to compare | BBLG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBBLGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −2.2x | −0.4x | |
PEG Ratio | 0.00 | 0.07 | 0.00 | |
Price/Book | 0.4x | 2.5x | 2.6x | |
Price / LTM Sales | - | 4.9x | 3.1x | |
Upside (Analyst Target) | - | 264.5% | 52.9% | |
Fair Value Upside | Unlock | 7.4% | 6.4% | Unlock |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.